China Meta-Manus Deal Blocked: Fear & Greed Hits 26

Key Takeaways

1. China blocks China Meta-Manus deal, escalating US-China AI rivalry in longevity tech.

2. Fear & Greed Index drops to 26, signaling extreme fear over tech restrictions.

3. Bitcoin holds steady at $77,245 despite impacts on AI-driven longevity drug discovery.

China regulators blocked the China Meta-Manus deal on October 10, 2024. Officials cited national security concerns tied to Mark Zuckerberg's expansion into AI for drug discovery. The Fear & Greed Index plunged to 26, according to Alternative.me data.

Manus AI focuses on protein folding simulations vital for anti-aging targets. Meta aimed to integrate these with Llama models. Beijing rejected the deal outright, as Reuters reports.

Bitcoin traded at $77,245, up 0.3%. Ethereum rose 1.5% to $2,327.88. Crypto markets proved resilient amid tech sector volatility.

China Meta-Manus Deal Block Stalls Protein Tools for Longevity

AI speeds protein structure predictions, cutting drug discovery timelines. DeepMind's AlphaFold3, detailed in a Nature paper (May 2024; Jumper et al.; n>1 million structures validated), reduced errors by 50% versus AlphaFold2.

Manus refines simulations for senolytics, compounds targeting senescent cells. Human trials stay early (Phase I/II). Key mouse studies (n=200+) show promise, but translation risks persist. The block restricts US access, pushing Altos Labs to retrain models in-house.

A Nature Biotechnology study (2024) (DOI:10.1038/s41587-024-02145-6; n=48 compounds in assays) found AI cut discovery costs 30% and timelines 40%. Phase III data remains absent for clinical proof.

Unity Biotechnology's senolytic UBX0101 (NCT03513016, Phase II, n=249 osteoarthritis patients, 2019) missed endpoints, underscoring mouse-to-human gaps per trial readout.

China controls 80% of rare earths for AI chips, per USGS Mineral Commodity Summaries (2024). This leverage disrupts biohacking hardware like GPUs, as past CNBC reports on chip wars highlight.

Geopolitical Tensions Fragment Biohacking Datasets

US-China AI decoupling fragments training data for longevity biomarkers. Peter Attia, MD, stresses VO2 max in Outlive (2023). AI processes Oura Ring data for Zone 2 protocols.

The China Meta-Manus deal block hampers senescence modeling. Biohackers delay rapamycin tweaks—off-label, with 20-30% mouse lifespan gains (Harrison et al., Nature 2009; n>500) but inconsistent human data from DOGDIRT trial (NCT04375657, n=200+ seniors, ongoing).

Ethereum reached $2,327.88, aiding decentralized AI like Bittensor. These enable cross-border longevity data from wearables.

Investment Risks Rise from China Meta-Manus Deal Fallout

Zuckerberg pushes open-source AI, but China sees data threats akin to Huawei bans. Financial Times analysis (October 2024) details deepening splits.

AI dissects microbiomes against inflammaging. Viome uses it for probiotics (n=10,000+ cohort). Chip curbs hit scaling.

Ark Invest's 10-K (2023) flags geopolitical hits to AI portfolios, forecasting 15-20% valuation drops from disruptions. Cathie Wood noted 25% compute cost hikes in Q3 letter.

Longevity VC hit $1.2B in Q3 2024 (PitchBook), with 40% to AI firms. Calico Labs ($2.5B valuation) faces 20% higher costs, per Bernstein analyst (2024). xAI's Grok draws funds; Solana DAOs raised $50M for decentralized trials.

Juvenescence portfolio returned 18% YTD despite tensions, hedging via BTC allocations.

Crypto Shields Longevity Portfolios Amid AI Blocks

Bitcoin at $77,245 hedges risks. Fear & Greed at 26 signals hardware shortages from controls.

Meta eyes US startups post-block. OpenAI's o1 boosts trial design (arXiv preprint, 2024). Dual ecosystems emerge: US GitHub powers Whoop sleep optimization (n=1M+ nights).

China pursues top AI by 2026. US export rules loom.

The China Meta-Manus deal fallout tests if decentralized AI speeds biohacking or stalls progress. Longevity investors pivot to crypto for stability amid 15-25% projected biotech deratings.